US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
Total Current Liabilities
Modalis Therapeutics Corp
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Modalis Therapeutics Corp
TSE:4883
|
Total Current Liabilities
ÂĄ198.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Total Current Liabilities
ÂĄ10.8B
|
CAGR 3-Years
52%
|
CAGR 5-Years
25%
|
CAGR 10-Years
43%
|
|
PeptiDream Inc
TSE:4587
|
Total Current Liabilities
ÂĄ10.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
55%
|
CAGR 10-Years
54%
|
|
Takara Bio Inc
TSE:4974
|
Total Current Liabilities
ÂĄ7.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Total Current Liabilities
ÂĄ873.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
S
|
StemRIM Inc
TSE:4599
|
Total Current Liabilities
ÂĄ217.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
See Also
What is Modalis Therapeutics Corp's Total Current Liabilities?
Total Current Liabilities
198.1m
JPY
Based on the financial report for Dec 31, 2023, Modalis Therapeutics Corp's Total Current Liabilities amounts to 198.1m JPY.
What is Modalis Therapeutics Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
54%
Over the last year, the Total Current Liabilities growth was 40%. The average annual Total Current Liabilities growth rates for Modalis Therapeutics Corp have been 50% over the past three years , 54% over the past five years .